One-hundred eight-six patients with Primary Myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden with outcome variables, including time to anemia, leukocytosis, leukopenia, thrombocytopenia, massive splenomegaly, leukemia, and with overall survival.
INTRODUCTION
Sixty-percent of patients with Primary Myelofibrosis (PMF) present an acquired recurrent mutation located in exon 14 of JAK2 (JAK2V617F) [1] [2] [3] [4] ; an additional 8-10% harbor a mutation at codon 515 in MPL, ie W515L/K/A [5] [6] [7] . These mutations represent a major criteria for diagnosis according to the 2008 WHO classification of myeloid neoplasms 8 ;
however, they are not specific of this disorder and are shared by other Philadelphiachromosome negative myeloproliferative neoplasms (MPNs), which include polycythemia vera (PV), essential thrombocythemia (ET) and refractory anemia with ring sideroblasts and thrombocytosis (RARS-T).
A JAK2V617F mutated genotype as well as different V617F allele burden have been variably associated with unique hematological and clinical characteristics in patients with PV or ET (reviewed in 9 ). In particular, it has been shown that increasing amount of V617F allele corresponded to a more pronounced myeloproliferative phenotype favoring higher hemoglobin level and leukocyte count, delineating a "continuum" of the two disorders 10 . Furthermore, the higher the mutational burden the higher the risk of presenting aquagenic pruritus, developing splenomegaly, suffering from thrombosis, requiring cytotoxic therapy, or transforming to post-PV/post-ET myelofibrosis 9 .
On the contrary, information in the setting of PMF is limited to a few studies that generally included patients genotyped at different times from diagnosis and used qualitative or semiquantitative assays [11] [12] [13] ; therefore, biases due to disease duration and previous therapy on hematological and clinical phenotype and on patients' outcome, as well as the effects of different mutated allele load, could not be adequately controlled. Only one recent study employed a quantitative assay for measuring allele burden and evaluating its clinical correlates 14 . Aim of current study was to analyze the prognostic relevance of JAK2V617F mutational status and of mutated allele burden in a population of newly-diagnosed patients with PMF.
PATIENTS AND METHODS

Patients
This study involved 186 patients with a diagnosis of PMF satisfying the 2008 World Health
Organization (WHO) criteria 15 . Patients were eligible to enter the study if they had a blood sample collected for JAK2V617F genotyping at the time of diagnosis or within the following inter-and intra-assay variation was 3% and 5%, respectively.
Statistical analysis
The JAK2 mutated allele burden was considered as an ordered categorical variable based on the following groups: 0 (JAK2 wild-type patients), 1 to 25 percent, greater than 25% to 50%, greater than 50% to 75% and greater than 75%.
We used the chi-square 
Association of V617F mutated genotype or mutated allele burden with hematological and clinical characteristics
At presentation, patients harboring JAK2V617F mutation had significantly higher hemoglobin level (P<.0001), leukocyte count (P=.009) and platelet count (P=.02) compared to those without the mutation (Table 1) . Accordingly, the proportion of anemic patients (hemoglobin <100 g/L) at presentation was significantly lower among JAK2V617 mutated patients compared to wild-types (22% versus 44%; P= .03). By considering the different categories of patients in dependence of the V617F allele burden, we observed a statistically significant correlation with leukocytosis (P=.03) and an almost significant trend for higher hemoglobin level (P=.05) ( Table 2) . On the contrary, we found no impact of the mutated genotype or the mutated allele burden on other hematological parameters including peripheral blasts >1%, LDH level, and circulating CD34 + cells. JAK2V617F mutated and wild-type patients did not differ each to the other as concerned the presence of a palpable splenomegaly greater than 15 cm from LCM or of constitutional symptoms;
however, considering the group of mutated patients only, the frequency of those with large splenomegaly or constitutional symptoms increased significantly in relation to V617F allele burden (P=.003 and P=.04, respectively; Table 2 ).
To analyze whether the JAK2V617F mutational status correlated with prognostic scoring systems we evaluated the distribution of patients in the different risk categories of the Dupriez 18 or Cervantes 19 score; however, due to the relatively low number of patients in the quartiles of V617F allele burden we abstained from performing subgroup analysis.
We observed that the number of JAK2V617F mutated patients in the low risk category of
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From the Dupriez scoring system was significantly greater compared to un-mutated patients (P=.017), possibly due to the higher hemoglobin level found in mutated patients; on the other hand, the distribution of patients in the four risk categories of Cervantes score was independent of JAK2V617F mutational status.
Association of V617F mutated genotype or mutated allele burden with disease progression
To investigate the impact of JAK2V617F mutational status or categorized V617F allele burden on parameters associated with disease progression we calculated the time elapsing from diagnosis to hematological and clinical outcome events which included: changes in hematological parameters not due to cytoreductive therapy (anemia, defined as an hemoglobin steadily <100 g/L; leukopenia, as a leukocyte count <4x10 9 /L; leukocytosis, as a leukocyte count >25x10 9 /L; thrombocytopenia, as a platelet count The relevance of different V617F allele burden on those outcomes was also evaluated. We found that patients in the lower quartile had significantly shorter time to anemia (P=.02) and leukopenia (P=.004) compared to upper quartiles ( Figure 2) ; the corresponding RR figures were 2.11 (95%CI 1.1-4.43) for anemia and 6.84 (95% CI 1.9-24.59) for leukopenia. We also found that time to large splenomegaly was significantly shorter in patients of the upper quartiles as compared to the lower quartile (P=.02); only one of 17 patients in the lower quartile (5.8%) developed large splenomegaly during the follow-up compared to 16.2%, 25.8%, and 25.0% in the other quartiles ( Figure 3 and Table   2 ). On the other hand, there was no significant difference in the time to leukemia
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Association of V617F mutated genotype or mutated allele burden with disease outcome
After a median follow-up of 17.2 months, there were 23 patients (12.3%) who died, accounting for 13.5% and 11.8% of the JAK2 wild-type and JAK2V617F mutated, respectively (P=.64; Table 1 ). Transformation to acute leukemia was the reason of death in 15 of them (65% of all deaths), accounting for 10.1% and 7.1% of JAK2 wild-type and JAK2V617F mutated patients, respectively (P=.078). Duration of survival was similar in JAK2 wild-type and JAK2V617F mutated patients (P=.73; Figure 3A ). However, when we analyzed JAK2V671F mutated patients after stratification according to the burden of V617F allele, we found that survival was significantly shorter in the lower quartile compared to upper quartiles (P=.0001, Figure 3B ) as well as to JAK2 wild-type patients (P=.006; Figure 3A) . The percentage of patients in the lower quartile who died was as high as 35.3% compared to 16.3%, 3.2% and 2.8% in upper quartiles, respectively (P=.007, Table 2 ). Causes of death in the lower quartile were represented by systemic infections or sepsis (n= 5) and multi-organ failure (n= 1), while no case of leukemia transformation was observed. The distribution of patients with favorable or unfavorable cytogenetic abnormalities according to their V617F allele burden is presented in Table 3 ; there was no statistically significant preferential clustering of unfavorable cytogenetic abnormalities in any of the different allele burden categories (P= .073, chi-square test for trend).
Variables which were associated with overall survival in univariate and multivariate analysis are listed in Table 4 . Age, PB blast count, and a lower V617F allele burden maintained their significant association with survival in multivariate analysis; of note, there was an almost significant association of hemoglobin level (HR 0.60, 95% CI 0.36-1.01; P =.051) with survival.
DISCUSSION
Primary myelofibrosis is associated with poorer prognosis compared to other classic BCR/ABL negative chronic myeloproliferative neoplasms due to a substantial reduction of life expectancy 21 in the order of 31% compared to gender-and age-adjusted control population 22 . However, survival may range from a few months to an excess of decade, especially in younger patients [23] [24] [25] . The discovery of the JAK2V617F mutation and its association with distinct hematological and clinical characteristics prompted further research to assessing the predictive value of mutational status for the most common complications of PV or ET, ie vascular events, and for prognosis and survival more in general. The latter aspect is particularly relevant for PMF, owing that survival in PV or ET may be only slightly reduced compared to normal population. The purpose of present study was to evaluate the consequence of JAK2V617F mutational status and V617F mutated allele burden on disease outcome in a population of newly diagnosed patients with PMF. Similar to observations made in PV or ET, also in this series of PMF patients we found statistically significant association of the JAK2V617F mutated status with a more pronounced myeloproliferative phenotype favoring raised hemoglobin level and leukocyte count; accordingly, the time to developing anemia or leukopenia during the follow-up was significantly longer, and conversely the time to develop leukocytosis significantly shorter, in mutated patients. These findings were generally in agreement with results from English 11 and GIMEMA 13 group, and at variance with the Mayo Clinic series 12,14 in which hemoglobin level were not significantly modified by the presence of mutation 14 . We also found that patients presenting anemia at diagnosis were significantly less frequent among JAK2V617F mutated than wild-type, and this probably accounted for more mutated patients to be included within the low-risk category according to Lille score system. However, the main outcome events of the study, namely overall survival and leukemia 11 . Also in the GIMEMA study 13 overall survival was not influenced by a JAK2V617F mutated status although a higher rate of leukemic transformation was observed; the reason for these discrepancies are not obvious, and might be generically ascribed to series variability. Therefore, a conclusion of present study is that a JAK2V617F mutated status per se does not reflect in a poorer prognosis in PMF.
However, the fact that overall survival in JAK2V617F mutated patients was similar to wild-type patients notwithstanding their higher hemoglobin level, which is considered as one major factor influencing survival in PMF, suggested possible heterogeneity within the category of mutated patients. Similarly, a correlation of JAK2V617F mutated status with outcome events, including thrombosis, in patients with PV resulted evident only after stratification according to their burden of mutated allele at diagnosis 28, 29 . Therefore, in this study we used a sensitive real-time PCR approach to stratifying PMF patients in quartiles of burden of mutated allele at presentation. We found that patients included in the lower quartile showed significantly shorter progression time to anemia, leukopenia, and conversely longer time to large splenomegaly, when compared to upper quartiles. More importantly, we found a striking difference in overall survival that was significantly reduced in patients of the lower quartile compared not only to upper quartiles but also to JAK2 wildtype patients. Reduced survival was not due to leukemic transformation (no patient in the lower quartile evolved to leukemia) but mainly to systemic infections. Thus, patients in the lower quartiles apparently died because of the consequences of bone marrow failure, as indirectly suggested by the shorter time to developing leukopenia. The poorer survival of patients harboring low JAK2V617F allele burden was first described in a study from Mayo In summary, results of this study validate and extend recent report 14 and point to a low JAK2V617F allele burden at diagnosis as a strong surrogate marker associated with shortened survival in PMF; at present, the biologic mechanisms underlying this correlation remain fully to be established. One additional implication of our findings is that, while JAK2 genotyping is recommended in the diagnostic work-up of suspected PMF according to the WHO classification, a quantitative rather than a qualitative assay would be more appropriate. In this regard, an initiative of the European Leukemia Net working group is undergoing with the aim to harmonize different JAK2V617F quantitation methods; indeed, a recent multicenter study found that several of the quantitative assays described in the literature produced discrepant results 30 . As a matter of fact, finding a low JAK2V617F allele burden at diagnosis would point to a poorer prognosis that can not be appropriately recognized by current score systems. This information might drive early therapeutic decisions, involving the use of stem cell transplantation in younger patients and/or patient inclusion in trials with investigational drugs. However, we acknowledge that a preferential clustering of low-allele burden subjects in the high-risk category of the IWG-MRT scoring system might have been missed due to the relatively small size of our patient population.
Therefore, we suggest the opportunity of a large prospective study on well-characterized population of patients and with standardized JAK2V617F quantitation method, which might ideally find place within international consortia and potentially provide definite information within a relatively short time.
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